The HCV Race: Gilead Plowing Ahead With ‘7977; Bristol Eyes First-To-Market Opportunity With All-Oral Combo In Asia
This article was originally published in PharmAsia News
Executive Summary
Several companies developing candidates for hepatitis C updated their plans during the recent round of quarterly earnings calls, outlining everything from strategies to be first-to-market with an all-oral combination of direct-acting antivirals to an emerging market strategy for pegylated interferon.